| 前收市價 | 8.00 |
| 開市 | 7.93 |
| 買盤 | 7.98 x 1000 |
| 賣出價 | 8.01 x 1000 |
| 今日波幅 | 7.91 - 8.49 |
| 52 週波幅 | 1.52 - 11.25 |
| 成交量 | |
| 平均成交量 | 4,141,849 |
| 市值 | 5.623B |
| Beta 值 (5 年，每月) | -1.03 |
| 市盈率 (最近 12 個月) | 21.08 |
| 每股盈利 (最近 12 個月) | 0.38 |
| 業績公佈日 | 2024年8月07日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 10.67 |
Motley Fool3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
These high-flying stocks could have more room to run if analysts are right.
ZacksSummit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
BenzingaSummit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
